The lung microbiome after lung transplantation

Expert Review of Respiratory Medicine

Volumn 8, Issue 2, 2014, Pages 221-231

  Becker, Julia ^a   Poroyko, Valeriy ^b   Bhorade, Sangeeta ^c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

bacterial infections; bronchiolitis obliterans syndrome; fungome; lung transplant; microbiome; viral infections; virome

Indexed keywords

AZITHROMYCIN;

ALLOGRAFT; ASPERGILLUS; BRONCHIOLITIS OBLITERANS; DIGESTIVE SYSTEM; FUNGAL COMMUNITY; GRAFT RECIPIENT; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; INFECTION RISK; INTESTINE GRAFT; LIVER TRANSPLANTATION; LUNG MICROBIOME; LUNG TRANSPLANTATION; MICROBIAL COMMUNITY; MICROBIOLOGY; MICROBIOME; MIXED INFECTION; ORGAN DONOR; PSEUDOMONAS; REVIEW; RISK ASSESSMENT; SAMPLING; STEM CELL TRANSPLANTATION; SURVIVAL; TREATMENT INDICATION; UPPER RESPIRATORY TRACT;

BRONCHIOLITIS OBLITERANS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; LUNG; LUNG TRANSPLANTATION; MICROBIOTA; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84896782301     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.890518     Document Type: Review

References (80)

1. Yusen RD, Christie JD, Edwards LB, et al. The registry of the international society for heart and lung transplantation: thirtieth adult lung and heart-lung transplant report-2013; focus theme: age. J Heart Lung Transplant 2013;32(10):965-788
2. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012;31(10):1073-866
3. Christie JD, Edwards LB, Kucheryavaya AY, et al. The registry of the international society for heart and lung transplantation: twenty-eighth adult lung and heart-lung transplant report - 2011. J Heart Lung Transplant 2011;30(10):1104-222
4. Orens JB, Garrity ER. Jr. General overview of lung transplantation and review of organ allocation. Proc Am Thorac Soc 2009;6(1): 13-199
5. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. Transplantation 2008;85(5):771-44
6. Chambers DC, Davies B, Mathews A, et al. Bronchiolitis obliterans syndrome, hypogammaglobulinemia, and infectious complications of lung transplantation. J Heart Lung Transplant 2013;32(1): 36-433
7. Gottlieb J, Schulz TF, Welte T, et al. Community-acquired respiratory viral infections in lung transplant recipients: a single season cohort study. Transplantation 2009;87(10):1530-77
8. Gregson AL, Wang X, Weigt SS, et al. Interaction between Pseudomonas and CXC chemokines increases risk of bronchiolitis obliterans syndrome and death in lung transplantation. Am J Respir Crit Care Med 2013;187(5):518-266
9. Hayes D Jr, Mansour HM, Kirkby S, Phillips AB. Rapid acute onset of bronchiolitis obliterans syndrome in a lung transplant recipient after respiratory syncytial virus infection. Transpl Infect Dis 2012;14(5):548-500
10. Khalifah AP, Hachem RR, Chakinala MM, et al. Respiratory viral infections are a distinct risk for bronchiolitis obliterans syndrome and death. Am J Respir Crit Care Med 2004;170(2):181-77
11. Kroshus TJ, Kshettry VR, Savik K, et al. Risk factors for the development of bronchiolitis obliterans syndrome after lung transplantation. J Thorac Cardiovasc Surg 1997;114(2):195-2022
12. Shalhoub S, Husain S. Communityacquired respiratory viral infections in lung transplant recipients. Curr Opin Infect Dis 2013;26(4):302-88
13. Snyder LD, Finlen-Copeland CA, TurbyfillWJ, et al. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med 2010;181(12):1391-66
14. Aagaard K, Petrosino J, Keitel W, et al. The human microbiome project strategy for comprehensive sampling of the human microbiome and why it matters. FASEB J 2013;27(3):1012-222
15. Morgan XC, Huttenhower C. Chapter 12: human microbiome analysis. PLoS Comput Biol 2012;8(12):e10028088
16. DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006;72(7):5069-722
17. Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Exp Rev Res Med 2013;7(3):245-577
18. Goddard AF, Staudinger BJ, Dowd SE, et al. Direct sampling of cystic fibrosis lungs indicates that DNA-based analyses of upper-airway specimens can misrepresent lung microbiota. Proc Natl Acad Sci USA 2012;109(34):13769-744
19. Cabrera-Rubio R, Garcia-Nunez M, Seto L, et al. Microbiome diversity in the bronchial tracts of patients with chronic obstructive pulmonary disease. J Clin Microbiol 2012; 50(11):3562-88
20. Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med 2011;184(8):957-633
21. Morris A, Beck JM, Schloss PD, et al. Comparison of the respiratory microbiome in healthy non-smokers and smokers. Am J Respir Crit Care Med 2013;187(10): 1067-755
22. Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the "healthy" smoker and in COPD. PLoS ONE 2011;6(2):e163844
23. Rogers G, Van Der Gast C, Hopkins P, et al. The lower airway bacterial microbiota in patients with and without bronchiolitis obliterans syndrome following lung transplantation. In: C14. clinical and translational advances in lung transplantation. American Thoracic Society; 2013. p. A37800
24. Pezzulo AA, Nassar B, Gansemer ND, et al. A diverse landscape of DNA from live and dead bacteria in the airways. In: C56. bench to bedside advances in bronchiectasis. American Thoracic Society; p. A64066
25. Borewicz K, Pragman AA, Kim HB, et al. Longitudinal analysis of the lung microbiome in lung transplantation. FEMS Microbiol Lett 2013;339(1):57-655
26. Sze MA, Dimitriu PA, Hayashi S, et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;185(10):1073-800
27. Han MK, Erb-Downward J, Zhou Y, et al. The IPF microbiome: analysis from the COMET study. In: C13. influence of the microbiome on airway mucosal responses in health and disease. American Thoracic Society; 2013. p. A37699
28. Molyneaux PL, Russell AM, Cox MJ, et al. The respiratory microbiome in idiopathic pulmonary fibrosis. In: C103. pathogenesis, biomarkers, and risk factors for interstitial lung disease: from bench to bedside. American Thoracic Society; 2012. p. A51744
29. Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One 2012;7(9):e450011
30. Tunney MM, Einarsson GG, Wei L, et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med 2013;187(10):1118-266
31. Vital D, Hofer M, Benden C, et al. Impact of sinus surgery on pseudomonal airway colonization, bronchiolitis obliterans syndrome and survival in cystic fibrosis lung transplant recipients. Respiration 2013; 86(1):25-311
32. Alexander BD, Petzold EW, Reller LB, et al. Survival after lung transplantation of cystic fibrosis patients infected with Burkholderia cepacia complex. Am J Transplant 2008;8(5):1025-300
33. Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001;164(11):2102-66
34. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001;163(1):43-88
35. De Soyza A, Meachery G, Hester KL, et al. Lung transplantation for patients with cystic fibrosis and Burkholderia cepacia complex infection: a single-center experience. J Heart Lung Transplant 2010;29(12):1395-4044
36. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001; 153(4):345-522
37. Dickson RP, Erb-Downward J, Britt ZE, et al. The lung microbiota is distinct following lung transplantation and is associated with bronchiolitis obliterans syndrome. In: A104. lung transplantation: clinical and translational advances. American Thoracic Society; 2013. p. A22099
38. Willner DL, Hugenholtz P, Yerkovich ST, et al. Reestablishment of recipient-associated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2013;187(6):640-77
39. Fisichella PM, Davis CS, Kovacs EJ. A review of the role of GERD-induced aspiration after lung transplantation. Surg Endosc 2012;26(5):1201-44
40. Garrity ER Jr. Gastroesophageal reflux disease and bronchiolitis obliterans syndrome: where are we today? J Heart Lung Transplant 2013;32(6):579-800
41. Hartwig MG, Davis RD. Gastroesophageal reflux disease-induced aspiration injury following lung transplantation. Curr Opin Organ Transplant 2012;17(5):474-88
42. Hoppo T, Komatsu Y, Jobe BA. Gastroesophageal reflux disease and patterns of reflux in patients with idiopathic pulmonary fibrosis using hypopharyngeal multichannel intraluminal impedance. Dis Esophagus 2012. [Epub ahead of print]
43. Murthy SC, Nowicki ER, Mason DP, et al. Pretransplant gastroesophageal reflux compromises early outcomes after lung transplantation. J Thorac Cardiovasc Surg 2011;142(1):47-52.e433
44. Charlson ES, Diamond JM, Bittinger K, et al. Lung-enriched organisms and aberrant bacterial and fungal respiratory microbiota after lung transplant. Am J Respir Crit Care Med 2012;186(6):536-455
45. Luna RA, Sagar M, Crabtree SA, et al. Characterization of the lung microbiome in pediatric lung transplant recipients. J Heart Lung Transplant 2013;32(4 Supplement): S2911
46. Dickson RP, Britt ZE, Erb-Downward J, et al. Lung microbiota diversity is decreased among lung transplant recipients. In: C14. clinical and translational advances in lung transplantation. American Thoracic Society; 2013. p. A37811
47. Willner D, Ab-Ghani NA, Yerkovich S, et al. Longitudinal holistic profiling of the lung transplant microbiome. J Heart Lung Transplant 2013;32(4 Suppl):S10-111
48. Todd JL, Palmer SM. Bronchiolitis obliterans syndrome: the final frontier for lung transplantation. Chest 2011;140(2): 502-88
49. Willner D, Hugenholtz P, Tan ME, et al. distinct microbial signatures of healthy and failing lung allografts. J Heart Lung Transplant 2012;31(4 Suppl):S322
50. Poroyko V, Semenyuk E, Xu Z, et al. Longitudinal study of pulmonary microbial dynamics in lung transplant recipients with and without bronchiolitis obliterans syndrome. J Heart Lung Transplant 2013; 32(4 Suppl):S344
51. Hayes D Jr, Weiland A, Kirkby S, et al. Gram-negative infection and bronchiectasis in lung transplant recipients with bronchiolitis obliterans syndrome. Thorac Cardiovasc Surg 2013;61(3):240-55
52. Vos R, Vanaudenaerde BM, Geudens N, et al. Pseudomonal airway colonisation: risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur Respir J 2008;31(5):1037-455
53. Gottlieb J, Mattner F, Weissbrodt H, et al. Impact of graft colonization with gramnegative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir Med 2009;103(5):743-99
54. Jain R, Hachem RR, Morrell MR, et al. Azithromycin is associated with increased survival in lung transplant recipients with bronchiolitis obliterans syndrome. J Heart Lung Transplant 2010;29(5):531-77
55. Murphy DM, Forrest IA, Corris PA, et al. Azithromycin attenuates effects of lipopolysaccharide on lung allograft bronchial epithelial cells. J Heart Lung Transplant 2008;27(11):1210-166
56. Garantziotis S, Howell DN, McAdams HP, et al. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest 2001;119(4):1277-800
57. Halloran K, Chang J, Kapasi A, et al. Predictors of chronic lung allograft dysfunction (CLAD) following respiratory viral infection (RVI). In: The International Society for heart and lung transplantation. 33rd Annual Meeting and Scientific Sessions; Montréal, QC, CA, USA;2013
58. Kumar D, Husain S, Chen MH, et al. A prospective molecular surveillance study evaluating the clinical impact of community-acquired respiratory viruses in lung transplant recipients. Transplantation 2010;89(8):1028-333
59. Neurohr C, Huppmann P, Leuchte H, et al. Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome? Am J Transplant 2005;5(12):2982-911
60. Engelmann I, Welte T, Fuhner T, et al. Detection of Epstein-Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation. J Clin Virol 2009;45(1):47-533
61. Westall GP, Michaelides A, Williams TJ, et al. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation 2003;75(12):2064-88
62. Paraskeva M, Bailey M, Levvey BJ, et al. Cytomegalovirus replication within the lung allograft is associated with bronchiolitis obliterans syndrome. Am J Transplant 2011;11(10):2190-66
63. Fiser SM, Tribble CG, Long SM, et al. Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome. Ann Thorac Surg 2002;73(4):1041-7.discussion 1047-10488
64. Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004;170(10):1120-33
65. Manuel O, Kumar D, Moussa G, et al. Lack of association between beta-herpesvirus infection and bronchiolitis obliterans syndrome in lung transplant recipients in the era of antiviral prophylaxis. Transplantation 2009;87(5):719-255
66. Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008;46(6): 831-99
67. Ruttmann E, Geltner C, Bucher B, et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 2006;81(10):1415-200
68. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant 2009;9(8): 1903-111
69. Ames NJ, Sulima P, Ngo T, et al. A characterization of the oral microbiome in allogeneic stem cell transplant patients. PloS One 2012;7(10):e476288
70. Sheehy EC, Beighton D, Roberts GJ. The oral microbiota of children undergoing liver transplantation. Oral Microbiol Immunol 2000;15(3):203-100
71. Diaz PI, Hong BY, Frias-Lopez J, et al. Transplantation-associated long-term immunosuppression promotes oral colonization by potentially opportunistic pathogens without impacting other members of the salivary bacteriome. Clin Vaccine Immunol 2013;20(6):920-300
72. Murphy S, Nguyen VH. Role of gut microbiota in graft-versus-host disease. Leuk Lymphoma 2011;52(10):1844-566
73. Hartman AL, Lough DM, Barupal DK, et al. Human gut microbiome adopts an alternative state following small bowel transplantation. Proc Natl Acad Sci USA 2009;106(40):17187-922
74. Wu ZW, Ling ZX, Lu HF, et al. Changes of gut bacteria and immune parameters in liver transplant recipients. Hepatobiliary Pancreat Dis Int 2012;11(1):40-500
75. Xie YR, Liu SL, Liu X, et al. Intestinal microbiota and innate immunity-related gene alteration in cirrhotic rats with liver transplantation. Transplant Proc 2011; 43(10):3973-99
76. Oh PL, Martinez I, Sun Y, et al. Characterization of the ileal microbiota in rejecting and nonrejecting recipients of small bowel transplants. Am J Transplant 2012;12(3):753-622
77. Xie Y, Luo Z, Li Z, et al. Structural shifts of fecal microbial communities in rats with acute rejection after liver transplantation. Microb Ecol 2012;64(2):546-544
78. Corbitt N, Kimura S, Isse K, et al. Gut bacteria drive Kupffer cell expansion via MAMP-mediated ICAM-1 induction on sinusoidal endothelium and influence preservation-reperfusion injury after orthotopic liver transplantation. Am J Pathol 2013;182(1):180-911
79. Wylie KM, Weinstock GM, Storch GA. Emerging view of the human virome. Transl Res 2012;160(4):283-900
80. Willner D, Thurber RV, Rohwer F. Metagenomic signatures of 86 microbial and viral metagenomes. Environ Microbiol 2009;11(7):1752-666